FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Investment analysts at Brookline Capital Management decreased their FY2028 EPS estimates for C4 Therapeutics in a report issued on Thursday, November 6th. Brookline Capital Management analyst L. Cann now expects that the company will earn $1.15 per share for the year, down from their prior forecast of $1.16. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share. Brookline Capital Management also issued estimates for C4 Therapeutics’ FY2029 earnings at $12.57 EPS.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. The business had revenue of $11.23 million during the quarter, compared to the consensus estimate of $6.28 million. C4 Therapeutics had a negative return on equity of 64.40% and a negative net margin of 395.51%.

A number of other research firms have also commented on CCCC. Wall Street Zen lowered C4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Barclays boosted their price target on shares of C4 Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Monday, September 22nd. Guggenheim began coverage on shares of C4 Therapeutics in a research report on Wednesday, September 3rd. They set a “buy” rating and a $8.00 price objective for the company. Wells Fargo & Company boosted their target price on shares of C4 Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, September 23rd. Finally, Zacks Research cut shares of C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 22nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.50.

C4 Therapeutics Trading Down 1.7%

NASDAQ CCCC opened at $2.34 on Monday. The firm has a market capitalization of $166.54 million, a PE ratio of -1.40 and a beta of 2.95. The business’s 50-day moving average price is $2.52 and its two-hundred day moving average price is $2.08. C4 Therapeutics has a 12 month low of $1.09 and a 12 month high of $6.20.

Institutional Trading of C4 Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CCCC. Dynamic Technology Lab Private Ltd bought a new position in shares of C4 Therapeutics in the second quarter valued at $31,000. Savant Capital LLC acquired a new stake in shares of C4 Therapeutics in the 2nd quarter worth about $38,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of C4 Therapeutics in the 2nd quarter worth about $40,000. Crestwood Advisors Group LLC bought a new position in C4 Therapeutics in the 2nd quarter valued at about $41,000. Finally, Brookstone Capital Management acquired a new position in C4 Therapeutics during the 2nd quarter valued at about $42,000. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.